Drug/Biologics Firm Performance Regarding Postmarketing Requirements By Debra A. McCurdy on 23 September 2009 Print:Email this postLike this postShare this post on LinkedIn The FDA has released its annual report on the status of drug and biological product postmarketing studies and clinical trials, as required by the Food and Drug Administration Modernization Act of 1997.